Dr. Scott Rocklage achieved a B.S in Chemistry at the University of California, Berkeley as well as a Ph.D in Chemistry from MIT. At MIT he was in charge of research in the workroom of Richard R. Schrock. He has an experience of more than 30 years in healthcare management. Through this he had tactical administration tasks that enabled the endorsement of FDA of three U.S. Fresh Drug Applications namely; Cubicin, Teslascan and Omniscan. He became part of 5AM Ventures in the year 2003 as an initiative partner and later on was managing partner in the year 2004. He has a continuous good career I the healthcare industry. He was the chairman and also CEO of Cubist Pharmaceuticals.
Dr Rocklage was part of R and D responsibilities at Catalytica and Salutar. At Nycomed he served as the CEO and also President. He previously was a chairman of the board of Relypsa as well as Novira. Furthermore he has board chairman of several firms, they include; Cidara, Rennovia, Cidara, Pulmatrix and Epirus. At Ilypsa that was received by Amgen he served as the executive chairman as well as Semprus and Miikana. Apart from being part of the world of healthcare, Scott Rocklage is a starter and co-starter of more than 30 U.S copyrights and moreover has over than 100 seen publications. He is from Boston at the MA office.
5AM Ventures is one of the top companies that deal with venture capital. It is dedicated to developing future science organizations that have the ability to supply unique revenues to their investors. They work together with firms as well as supporting them in finding solutions to essential healthcare requirements through pioneering innovations in science and medicine. The organization has a collection of companies that head original methods to identify, stop and treat a large occurrence of medical conditions.
The experts OF investment at 5AM have specific qualities that guide them in development, they are; medical, scientific, financial professionalism and operational. Their balanced backgrounds give them an extraordinary advantage in getting and forming life science selection of firms. The staff members are devoted to delivering their best in organization building and especially on initial investors. The organization has responsibilities of implementing firm strategies, business growth, fundraising and organization employment. They are also in charge of temporary tasks and they often participate as board members.
The investment tactics of 5AM are categorized into three sectors namely; medical technology, biopharmaceutical and research tools. These are for the purpose of the enhanced life science skills of health care at the company. Furthermore they add up creative podium technologies, products and business byproducts with growth series and thus investing in large therapeutic regions.